|FactSnippet No. 870,569|
19 Facts About Actelion
Actelion focuses on the manufacture of drugs that treat rare diseases and orphan diseases.
|FactSnippet No. 870,570|
One of the focuses of Actelion is treating individuals with pulmonary arterial hypertension, a heart condition that leaves patients with a short life expectancy even with treatment.
|FactSnippet No. 870,571|
Actelion scientists were among the first to work in the field of endothelian receptor antagonists.
|FactSnippet No. 870,572|
Actelion was initially financed with venture capital provided through a syndicate including Atlas Venture, Sofinnova and HealthCap.
|FactSnippet No. 870,573|
Actelion was founded in 1997 by husband and wife team Jean-Paul and Martine Clozel together with three colleagues after F Hoffmann-La Roche cut their funding for Martine's cardiovascular program.
|FactSnippet No. 870,576|
In November 2006, CoTherix and Actelion signed a merger plan, which was announced publicly; this followed the initiation of negotiations in August 2006.
|FactSnippet No. 870,577|
In January 2007, Actelion completed acquisition of all CoTherix stock, and summarily informed Asahi that work on fasudil would be terminated.
|FactSnippet No. 870,578|
Now, Actelion had a competitor blockbuster drug on the market, bosentan .
|FactSnippet No. 870,579|
Actelion was able to do this by illegally providing money to Medicare patients in order for them to be able to fulfill their co-payments for the drug Tracleer.
|FactSnippet No. 870,580|
Actelion was able to use the charity organization by the name of Caring Voice Coalition to send money only to those people who were receiving prescriptions of Tracleer.
|FactSnippet No. 870,581|
Actelion was complicit in referring patients to Caring Voice Coalition.
|FactSnippet No. 870,582|
Actelion has been reported to start working with Analytics 4 Life to use imaging technology with regards to pulmonary hypertension.
|FactSnippet No. 870,583|
Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases:.
|FactSnippet No. 870,584|
Actelion's shares have been listed on the SIX Swiss Exchange since 2000 SWX Swiss Exchange Swiss Leader Index.
|FactSnippet No. 870,585|
In September 2008, Actelion shares began trading as part of the Swiss Market Index.
|FactSnippet No. 870,586|